TWI837156B - 新穎的cd137及pd-l1特異性融合蛋白 - Google Patents

新穎的cd137及pd-l1特異性融合蛋白 Download PDF

Info

Publication number
TWI837156B
TWI837156B TW108127283A TW108127283A TWI837156B TW I837156 B TWI837156 B TW I837156B TW 108127283 A TW108127283 A TW 108127283A TW 108127283 A TW108127283 A TW 108127283A TW I837156 B TWI837156 B TW I837156B
Authority
TW
Taiwan
Prior art keywords
fusion protein
seq
nos
protein
amino acid
Prior art date
Application number
TW108127283A
Other languages
English (en)
Chinese (zh)
Other versions
TW202019967A (zh
Inventor
瑪尼那 帕弗里朵
路西亞 帕塔尼
達賀 艾力克斯 史寇勒
克里斯汀 羅瑟
尚恩 歐威爾
拉希妲 貝艾巴
馬龍 漢納
珍娜 派普
Original Assignee
德商皮里斯製藥有限公司
法商施維雅藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商皮里斯製藥有限公司, 法商施維雅藥廠 filed Critical 德商皮里斯製藥有限公司
Publication of TW202019967A publication Critical patent/TW202019967A/zh
Application granted granted Critical
Publication of TWI837156B publication Critical patent/TWI837156B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW108127283A 2018-07-31 2019-07-31 新穎的cd137及pd-l1特異性融合蛋白 TWI837156B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18186445.5 2018-07-31
EP18186445 2018-07-31
EP18204548.4 2018-11-06
EP18204548 2018-11-06

Publications (2)

Publication Number Publication Date
TW202019967A TW202019967A (zh) 2020-06-01
TWI837156B true TWI837156B (zh) 2024-04-01

Family

ID=67480227

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108127283A TWI837156B (zh) 2018-07-31 2019-07-31 新穎的cd137及pd-l1特異性融合蛋白

Country Status (28)

Country Link
US (1) US20210363257A1 (OSRAM)
EP (2) EP3830120B9 (OSRAM)
JP (1) JP7482488B2 (OSRAM)
KR (1) KR20210040103A (OSRAM)
CN (1) CN112789292A (OSRAM)
AU (1) AU2019315703A1 (OSRAM)
BR (1) BR112020025263A2 (OSRAM)
CA (1) CA3100119A1 (OSRAM)
CL (1) CL2021000207A1 (OSRAM)
CY (1) CY1126148T1 (OSRAM)
DK (1) DK3830120T5 (OSRAM)
ES (1) ES2948717T3 (OSRAM)
FI (1) FI3830120T3 (OSRAM)
HR (1) HRP20230590T2 (OSRAM)
HU (1) HUE062320T2 (OSRAM)
IL (1) IL279541A (OSRAM)
LT (1) LT3830120T (OSRAM)
MD (1) MD3830120T3 (OSRAM)
MX (1) MX2021000401A (OSRAM)
MY (1) MY200710A (OSRAM)
PH (1) PH12021550001A1 (OSRAM)
PL (1) PL3830120T3 (OSRAM)
RS (1) RS64343B9 (OSRAM)
SG (1) SG11202100989UA (OSRAM)
SI (1) SI3830120T1 (OSRAM)
TW (1) TWI837156B (OSRAM)
WO (1) WO2020025659A1 (OSRAM)
ZA (1) ZA202100125B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019388808A1 (en) * 2018-11-29 2021-06-17 Harbour Biomed Therapeutics Limited Anti-PD-L1 antibody preparation
US20220168387A1 (en) * 2019-03-29 2022-06-02 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
CN114555638B (zh) 2019-10-11 2023-08-22 南京维立志博生物科技有限公司 结合4-1bb的抗体及其用途
CN116249709A (zh) 2020-06-05 2023-06-09 皮里斯制药有限公司 靶向4-1bb的多聚体免疫调节剂
US20240084014A1 (en) * 2020-10-16 2024-03-14 Qlsf Biotherapeutics, Inc. Multispecific binding compounds that bind to pd-l1
MX2023008172A (es) * 2021-01-08 2023-07-18 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo biespecifico de forma heterodimerica similar a la estructura del anticuerpo natural anti-pd-l1/anti-4-1bb y preparacion del mismo.
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
CN115677858A (zh) * 2021-07-23 2023-02-03 合肥瀚科迈博生物技术有限公司 一种能够靶向cd137和pd-l1的双特异性抗体的用途
CN114736303A (zh) * 2022-03-17 2022-07-12 英诺湖医药(杭州)有限公司 抗pd-l1和4-1bb的双功能抗体及其医药用途
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
WO2024064713A1 (en) * 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228
CN116211860B (zh) * 2023-05-10 2023-08-22 细胞生态海河实验室 Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017123650A2 (en) * 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins
CN107082812A (zh) * 2017-03-29 2017-08-22 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
CN107820500A (zh) * 2015-05-04 2018-03-20 皮里斯制药有限公司 Cd137特异性的蛋白
CN108112253A (zh) * 2015-05-18 2018-06-01 皮里斯制药有限公司 抗癌融合多肽

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CN1170543C (zh) 1998-06-08 2004-10-13 弗·哈夫曼-拉罗切有限公司 PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US10927154B2 (en) * 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
AU2016258977C1 (en) * 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
EP3309177B1 (en) * 2016-03-04 2020-05-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof
US10059769B2 (en) * 2016-06-13 2018-08-28 I-Mab Anti-PD-L1 antibodies and uses thereof
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
WO2019042153A1 (zh) * 2017-09-01 2019-03-07 四川科伦博泰生物医药股份有限公司 重组双特异性抗体
WO2023000675A1 (zh) * 2021-07-23 2023-01-26 安徽安科生物工程（集团）股份有限公司 靶向pd-l1和4-1bb的双特异性抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107820500A (zh) * 2015-05-04 2018-03-20 皮里斯制药有限公司 Cd137特异性的蛋白
CN108112253A (zh) * 2015-05-18 2018-06-01 皮里斯制药有限公司 抗癌融合多肽
WO2017123650A2 (en) * 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins
CN107082812A (zh) * 2017-03-29 2017-08-22 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 A. Richter, E. Eggenstein, and A. Skerra, "Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins", FEBS Letters, Vol.588, Issue 2, 無, 12 November 2013, Pages 213-218 *
期刊 Christine Rothe and Arne Skerra, "Anticalin® Proteins as Therapeutic Agents in Human Diseasese", BioDrugs, Vol.32, No.3, 無, 10 May 2018, Pages 233-243; *

Also Published As

Publication number Publication date
MX2021000401A (es) 2021-03-25
BR112020025263A2 (pt) 2021-03-09
MY200710A (en) 2024-01-12
JP7482488B2 (ja) 2024-05-14
HRP20230590T1 (hr) 2023-09-15
RS64343B1 (sr) 2023-08-31
SG11202100989UA (en) 2021-02-25
RS64343B9 (sr) 2023-11-30
PL3830120T3 (pl) 2023-10-09
LT3830120T (lt) 2023-07-10
ES2948717T3 (es) 2023-09-18
HRP20230590T2 (hr) 2024-02-16
WO2020025659A1 (en) 2020-02-06
MD3830120T2 (ro) 2023-08-31
CA3100119A1 (en) 2020-02-06
CY1126148T1 (el) 2023-11-15
US20210363257A1 (en) 2021-11-25
IL279541A (en) 2021-01-31
AU2019315703A1 (en) 2020-12-10
PH12021550001A1 (en) 2021-09-27
DK3830120T3 (da) 2023-06-26
ZA202100125B (en) 2023-06-28
SI3830120T1 (sl) 2023-10-30
EP4249064A2 (en) 2023-09-27
CL2021000207A1 (es) 2021-08-13
MD3830120T3 (ro) 2023-11-30
TW202019967A (zh) 2020-06-01
EP4249064A3 (en) 2023-12-06
EP3830120B9 (en) 2023-08-30
FI3830120T3 (fi) 2023-06-13
HUE062320T2 (hu) 2023-10-28
EP3830120A1 (en) 2021-06-09
CN112789292A (zh) 2021-05-11
KR20210040103A (ko) 2021-04-12
DK3830120T5 (da) 2024-08-19
EP3830120B1 (en) 2023-05-24
JP2021533203A (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
EP3830120B9 (en) Novel fusion protein specific for cd137 and pd-l1
US12486330B2 (en) Fusion proteins specific for CD137 and GPC3
CN110305210B (zh) 新型抗体分子、其制备方法及其用途
KR20230020443A (ko) 4-1bb 표적화 다량체 면역조절제
TW202428603A (zh) 新穎的cd137及cd228特異性融合蛋白
RU2818349C2 (ru) Новый слитый белок, специфичный для cd137 и pd-l1
RU2814653C2 (ru) Новые слитые белки, специфические в отношении cd137 и gpc3
EA046634B1 (ru) Новый слитый белок, специфичный к cd137 и pd-l1
HK40044273B (en) Novel fusion protein specific for cd137 and pd-l1
HK40044273A (en) Novel fusion protein specific for cd137 and pd-l1
TW202334203A (zh) 新穎的ox40及pd-l1特異性融合蛋白
HK40053668A (en) Novel fusion protein specific for cd137 and pd-l1

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees